Clinical Data Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy pharminent June 15, 2026
Regulatory Pfizer’s Hympavzi secures FDA expanded indications for haemophilia pharminent June 9, 2026
Clinical Data Legend surges on early data for ‘in vivo’ lymphoma cell therapy pharminent June 3, 2026
M&A / Deals Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug pharminent June 2, 2026
Clinical Data ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma pharminent June 2, 2026
M&A / Deals CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine pharminent May 6, 2026
M&A / Deals Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis pharminent April 27, 2026
Clinical Data Novo’s late-stage sickle cell win piles pressure on competitors pharminent April 20, 2026
M&A / Deals Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data pharminent April 8, 2026
M&A / Deals Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug pharminent March 25, 2026
Clinical Data Karyopharm myeloma drug yields mixed data in myelofibrosis trial pharminent March 24, 2026
